[Hiring] Director, GI Analytics @Revolution Medicines

Role Description

Reporting to the Senior Director, GI Analytics & Insights, the Director, GI Analytics will serve as the analytics lead for Revolution Medicines’ GI cancer portfolio. This role will partner closely with Commercial, Medical Affairs, Market Access, Clinical Development, and Business Operations to generate actionable insights that inform portfolio strategy, launch readiness, commercialization planning, and business performance.

The role requires a strong understanding of the PDAC and CRC cancer treatment landscape, patient journey, biomarker-driven markets, and oncology data assets. This position is based at our Redwood City, CA headquarters, with flexibility for remote candidates willing to travel regularly to the office.

Responsibilities include:

• Lead analytics strategy and execution for Revolution Medicines’ GI cancer portfolio.
• Partner with cross-functional stakeholders to identify key business questions and translate them into analytical plans and actionable recommendations.
• Generate insights from patient-, physician-, claims-, EMR-, and market-level data to inform portfolio strategy, launch planning, and commercial decision-making.
• Develop analyses to understand patient identification, biomarker testing patterns, treatment sequencing, referral pathways, and barriers to adoption.
• Conduct market opportunity assessments, patient journey analyses, and competitive landscape evaluations to support strategic planning.
• Design and execute segmentation, targeting, and opportunity identification analyses to inform customer engagement strategies.
• Monitor evolving standards of care, treatment dynamics, and competitor activity across GI cancer indications.
• Partner with Forecasting, Market Research, and Competitive Intelligence colleagues to develop an integrated view of market performance and future growth opportunities.
• Lead development of key performance metrics, dashboards, and launch readiness assessments.
• Inform data acquisition and data strategy decisions to ensure availability of fit-for-purpose oncology data assets.
• Manage external analytics vendors and ensure timely delivery of high-quality analyses.
• Communicate insights and strategic implications to senior leadership through clear, concise, and compelling recommendations.
• Represent Revolution Medicines’ values in all internal and external interactions.

Qualifications

• Bachelor’s degree required; advanced degree preferred.
• 8+ years of experience in pharmaceutical, biotechnology, healthcare analytics, or management consulting.
• Oncology analytics experience required; GI cancer (PDAC and/or CRC) experience strongly preferred.
• Demonstrated expertise working with healthcare claims, EMR, specialty pharmacy, and other patient-level datasets.
• Experience supporting oncology product launches and pre-launch planning.
• Strong analytical, problem-solving, and strategic thinking skills.
• Proven ability to influence cross-functional teams and senior leadership.
• Excellent communication and presentation skills.
• Ability to thrive in a fast-paced, entrepreneurial environment.

Requirements

• MBA, MPH, MS, or PhD preferred.
• Deep understanding of PDAC and/or CRC and biomarker-driven oncology markets.
• Experience supporting targeted oncology therapies.
• Experience with advanced analytics, predictive modeling, AI/ML applications, or commercial forecasting.
• Prior experience in a growth-stage biotechnology company.

Benefits

• Base Pay Salary Range: $201,000 - $251,000 USD.
• Competitive cash compensation.
• Robust equity awards.
• Strong benefits.
• Significant learning and development opportunities.

Company Description

Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.